Nat-Eribulin 0.5 mg (Eribulin Mesylate SOLUTION) 0.5 MG

NAT-ERIBULIN 0.5 MG is an intravenous solution containing Eribulin Mesylate, used for specific medical conditions. This medication is manufactured by Natco Pharma (Canada) Inc. and is available in a 0.5 MG strength.

Strength

0.5 MG

Manufacturer / TM Owner

NATCO PHARMA (CANADA) INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

NAT-ERIBULIN 0.5 MG is primarily used in the treatment of certain types of cancer. Eribulin Mesylate, the active ingredient, is often prescribed for conditions where other treatments have not been effective. This medication works by targeting cancer cells to slow their growth and spread. Patients should consult their healthcare provider to determine if this medication is suitable for their specific condition.

Side Effects

Common effects of NAT-ERIBULIN 0.5 MG may include fatigue, nausea, and hair loss. Some patients may also experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. These effects can vary from person to person, and not everyone will experience them. It is important to discuss any concerns with a healthcare professional.

Precautions & Warnings

NAT-ERIBULIN 0.5 MG should be handled with care and administered by a healthcare professional. It is important to follow the prescribed dosage and administration instructions to minimize the risk of side effects. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their doctor.

Avoid Interactions

NAT-ERIBULIN 0.5 MG may interact with other medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be avoided as it may exacerbate certain side effects. Always consult a healthcare professional for personalized advice.

Frequently Asked Questions

NAT-ERIBULIN 0.5 MG is used in the treatment of certain types of cancer, particularly when other treatments have not been effective.

NAT-ERIBULIN 0.5 MG is administered intravenously by a healthcare professional.

Common side effects may include fatigue, nausea, hair loss, and peripheral neuropathy.

It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions.

Pregnant women or those planning to become pregnant should discuss the risks and benefits with their doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.